Montrone F, Fumagalli M, Boccassini L, Greco M, Caruso I
Minerva Med. 1983 Jun 23;74(26):1517-20.
Proglumetacin, 450 mg/day, was administered during 1 month to 32 rheumatoid arthritis patients in anatomical and functional stage II or III. Overall, more than 50% of pts responded to the treatment, in particular those in stage II, in whom Ritchie's articular index, nightly and daily pain significantly decreased. Those pts in stage III who did not respond to proglumetacin even when administered at high dose, did not respond to indomethacin, either. Tolerance resulted very good, as only 3 complaints of mild and transient epigastric pain and 1 of skin rash were observed, but no one related to the C.N.S. High efficacy and good tolerance set therefore proglumetacin aside from indomethacin, A.S.A. and most of the recent non steroidal anti-inflammatory agents.
对处于解剖学和功能II期或III期的32例类风湿性关节炎患者，给予450毫克/天的丙谷美辛，治疗1个月。总体而言，超过50%的患者对治疗有反应，尤其是II期患者，其里奇关节指数、夜间和日间疼痛明显减轻。III期那些即使高剂量使用丙谷美辛也无反应的患者，对吲哚美辛也无反应。耐受性非常好，仅观察到3例轻度短暂上腹部疼痛和1例皮疹投诉，但均与中枢神经系统无关。因此，丙谷美辛与吲哚美辛、阿司匹林和大多数近期非甾体抗炎药相比，具有高效和良好的耐受性。
